To confirm the inhibitory effect of probenecid on the tubular secretion of organic anions, the clearance of PAH was determined in sham-treated rats versus STN animals in the absence and presence of probenecid
Probenecid is the generic name for 4-[(dipropyl-amino)sulfonyl] benzoic acid
Probenecid inhibits the tubular secretion of penicillin and usually increases penicillin plasma levels by any route the antibiotic is given
This interaction has also been reported with acetyldigoxin [282]
Probenecid: Probenecid may increased blood levels of ampicillin by interfering with
Modeling showed a competitive inhibition of the renal tubular secretion of gemifloxacin by probenecid as the most likely mechanism of the interaction
The estimated K m and V max for the saturable part of renal elimination were 9
A 2 Probenecid is a uricosuric and renal tubular blocking agent
Probenecid inhibits the tubular secretion of penicillin and usually increases penicillin plasma levels by any route the antibiotic is given
Probenecid inhibited the renal tubular secretion of ciprofloxacin and M1, probably by a competitive mechanism and due to reaching >100-fold higher plasma concentrations
It inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels
Probenecid, p-(di-n-propylsulphamyl)-benzoic acid, was developed in 1949 with the purpose of decreasing the renal clearance of penicillin
It competitively blocks the active transport of organic acids in the renal tubules
In 1951, probenecid was developed as a competitive inhibitor of penicillin renal secretion and allowed physicians to slacken the antibiotic renal elimination and thus to maintain adequate drug levels for a longer time